ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025)

ARS Pharmaceuticals has disclosed Receivables - Other across 5 years of filings, most recently posting $4.3 million for Q3 2025.

• Receivables - Other for Q3 2025 came in at $4.3 million, up 2708.55% year-over-year; the trailing twelve-month figure through Sep 2025 was $4.3 million (up 2708.55% YoY), and the FY2024 annual result was $1.2 million, up 88.96% from the prior year.
• Receivables - Other came in at $4.3 million for Q3 2025 at ARS Pharmaceuticals, up from $2.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $4.3 million in Q3 2025 to a low of $122000.0 in Q2 2024.
• The 5-year median for Receivables - Other is $307000.0 (2023), against an average of $841000.0.
• Across the five-year window, Receivables - Other plunged 65.04% in 2024 and jumped 2708.55% in 2025, its largest moves.
• ARS Pharmaceuticals' Receivables - Other stood at $159000.0 in 2021, then jumped by 33.96% to $213000.0 in 2022, then surged by 206.1% to $652000.0 in 2023, then jumped by 88.96% to $1.2 million in 2024, then jumped by 246.51% to $4.3 million in 2025.
• The last three Receivables - Other figures came in at $4.3 million (Q3 2025), $2.0 million (Q2 2025), and $963000.0 (Q1 2025), per Business Quant data.